Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Glenmark Pharmaceuticals Ltd 2 CIN NO. L24299MH1977PLC019982 3 Report filed for FY 2024-2025 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2023-2024, 2024-2025 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2023-2024, 2024-2025 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Harish KuberDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- V S Mani Designation : -Executive Director and Global Chief Financial Officer Date: 28/04/2025